Page 72 - Read Online

Page 12 of 12 Ni et al. Hepatoma Res 2020;6:25 I http://dx.doi.org/10.20517/2394-5079.2020.14

hepatocellular carcinoma. Front Immunol 2016;7:690.
35. Wang P, Qin W, Liu T, Jiang D, Cui L, et al. PiggyBac-engineered T cells expressing a glypican-3-specific chimeric antigen receptor show
potent activities against hepatocellular carcinoma. Immunobiology 2020;225:151850.
36. Chen C, Li K, Jiang H, Song F, Gao H, et al. Development of T cells carrying two complementary chimeric antigen receptors against
glypican-3 and asialoglycoprotein receptor 1 for the treatment of hepatocellular carcinoma. Cancer Immunol Immunother 2017;66:475-89.
37. Guo X, Jiang H, Shi B, Zhou M, Zhang H, et al. Disruption of PD-1 enhanced the anti-tumor activity of chimeric antigen receptor T cells
against hepatocellular carcinoma. Front Pharmacol 2018;9:1118.
38. Pan Z, Di S, Shi B, Jiang H, Shi Z, et al. Increased antitumor activities of glypican-3-specific chimeric antigen receptor-modified T cells
by coexpression of a soluble PD1-CH3 fusion protein. Cancer Immunol Immunother 2018;67:1621-34.
39. Wu X, Luo H, Shi B, Di S, Sun R, et al. Combined antitumor effects of Sorafenib and GPC3-CAR T cells in mouse models of
hepatocellular carcinoma. Mol Ther 2019;27:1483-94.
40. Wang Y, Chen M, Wu Z, Tong C, Dai H, et al. CD133-directed CAR T cells for advanced metastasis malignancies: a phase I trial.
Oncoimmunology 2018;7:e1440169.
41. Sun B, Yang D, Dai H, Liu X, Jia R, et al. Eradication of hepatocellular carcinoma by NKG2D-based CAR-T cells. Cancer Immunol Res
2019;7:1813-23.
42. Zhang RY, Wei D, Liu ZK, Yong YL, Wei W, et al. Doxycycline inducible chimeric antigen receptor T cells targeting CD147 for
hepatocellular carcinoma therapy. Front Cell Dev Biol 2019;7:233.
43. Yoon JS, Song BG, Lee JH, Lee HY, Kim SW, et al. Adjuvant cytokine-induced killer cell immunotherapy for hepatocellular carcinoma:
a propensity score-matched analysis of real-world data. BMC Cancer 2019;19:523.
44. Wang L, Simons DL, Lu X, Tu TY, Solomon S, et al. Connecting blood and intratumoral Treg cell activity in predicting future relapse in
breast cancer. Nat Immunol 2019;20:1220-30.
45. Yu R, Yang B, Chi X, Cai L, Liu C, et al. Efficacy of cytokine-induced killer cell infusion as an adjuvant immunotherapy for
hepatocellular carcinoma: a systematic review and meta-analysis. Drug Des Devel Ther 2017;11:851-64.
46. Chen CL, Pan QZ, Zhao JJ, Wang Y, Li YQ, et al. PD-L1 expression as a predictive biomarker for cytokine-induced killer cell
immunotherapy in patients with hepatocellular carcinoma. Oncoimmunology 2016;5:e1176653.
47. Zhu W, Peng Y, Wang L, Hong Y, Jiang X, et al. Identification of alpha-fetoprotein-specific T-cell receptors for hepatocellular carcinoma
immunotherapy. Hepatology 2018;68:574-89.
48. Sun L, Guo H, Jiang R, Lu L, Liu T, et al. Engineered cytotoxic T lymphocytes with AFP-specific TCR gene for adoptive immunotherapy
in hepatocellular carcinoma. Tumour Biol 2016;37:799-806.
49. Tan AT, Yang N, Lee Krishnamoorthy T, Oei V, Chua A, et al. Use of expression profiles of HBV-DNA integrated into genomes of
hepatocellular carcinoma cells to select T cells for immunotherapy. Gastroenterology 2019;156:1862-76.e9.
50. Qasim W, Brunetto M, Gehring AJ, Xue SA, Schurich A, et al. Immunotherapy of HCC metastases with autologous T cell receptor
redirected T cells, targeting HBsAg in a liver transplant patient. J Hepatol 2015;62:486-91.
51. Tian W, Ma J, Shi R, Ren C, He J, et al. gammadelta T cell-mediated individualized immunotherapy for hepatocellular carcinoma
considering clinicopathological characteristics and immunosuppressive factors. Oncol Lett 2018;15:5433-42.
52. Kamiya T, Chang YH, Campana D. Expanded and activated natural killer cells for immunotherapy of hepatocellular carcinoma. Cancer
Immunol Res 2016;4:574-81.
53. Qian L, Wang N, Tian H, Jin H, Zhao H, et al. Dual Effects of cellular immunotherapy in inhibition of virus replication and prolongation
of survival in HCV-positive hepatocellular carcinoma patients. J Immunol Res 2016;2016:6837241.
54. Moehler M, Heo J, Lee HC, Tak WY, Chao Y, et al. Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients
with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE). Oncoimmunology
2019;8:1615817.